ADMA Biologics, Inc. (ADMA) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reveals strong financial performance with record high revenue and margins, optimistic guidance, and effective strategies for ASCENIV's growth. The Q&A section indicates positive analyst sentiment and successful third-party supply contracts. Despite some risks and uncertainties, the company's robust financial health, strategic partnerships, and growth prospects outweigh potential negatives, suggesting a positive stock price movement.
Key Financial Performance
Total Revenue (Full Year 2025) $510 million, representing 20% year-over-year growth. The growth was driven by disciplined execution across commercial, manufacturing, and financial platforms.
Adjusted EBITDA (Full Year 2025) $231 million, increasing 40% year-over-year. This reflects expanding operating leverage and cost management.
Adjusted Net Income (Full Year 2025) $161 million, increasing 35% year-over-year. This was due to structural margin improvements and cost management.
ASCENIV Net Revenue (Full Year 2025) $363 million, representing 51% year-over-year growth. The growth was driven by high demand, strong prescriber adoption, and broad payer access.
Gross Margin (Full Year 2025) 57.4%, compared to 51.5% in 2024. The improvement was driven by ASCENIV's growing mix contribution and yield-enhanced production.
Total Revenue (Q4 2025) $139.2 million, reflecting 18% year-over-year growth. This was attributed to ASCENIV's differentiation and market dynamics.
Gross Margin (Q4 2025) 63.8%, representing approximately 10% year-over-year improvement. This was due to yield-enhanced production and product mix shift.
Adjusted EBITDA (Q4 2025) $73.6 million, growing by 52% year-over-year. This reflects operational leverage and cost management.
Adjusted Net Income (Q4 2025) $52.6 million, growing by 57% year-over-year. This was driven by structural margin improvements and operational efficiency.
Cash Balance (End of 2025) $88 million, largely excluding proceeds from the plasma center divestiture. The balance reflects disciplined capital allocation and operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ASCENIV net revenue: $363 million in 2025, representing 51% year-over-year growth. High demand and strong prescriber adoption are driving record utilization levels.
SG-001 pipeline asset: Potential $300 million to $500 million peak annual revenue opportunity. Pre-IND package submission anticipated in 2026.
ASCENIV market penetration: Still early in its penetration curve with broad payer access and increasing confidence in long-term supply continuity. Expected sustained utilization growth in 2026 and beyond.
Yield-enhanced production: Fully integrated into commercial operations in 2025, supporting meaningful gross margin growth and increasing earnings power.
Plasma collection network: Repositioned to improve capital efficiency and secure long-term high-titer plasma supply. Agreement to monetize 3 plasma centers while retaining ownership of 7 centers, with access to over 280 plasma collection centers.
Leadership transition: Appointment of Terry Kohler as CFO and Treasurer, focusing on working capital optimization and financial strategy.
Financial guidance: 2026 revenue expected to exceed $635 million, adjusted net income to exceed $255 million, and adjusted EBITDA to exceed $360 million. 2027 revenue expected to exceed $775 million.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Working Capital Challenges: The company expects accounts receivable and days sales outstanding to improve over the course of 2026, but the recent increase in working capital reflects the growth in ASCENIV and acceleration in revenue growth. This indicates potential short-term liquidity or cash flow management challenges.
Plasma Collection Network Repositioning: The strategic repositioning of the plasma collection network, including the monetization of 3 plasma centers, could pose risks related to operational disruptions or dependency on external suppliers for high-titer plasma.
Regulatory and Compliance Risks: The company’s reliance on FDA lot releases and compliance with regulatory standards for yield-enhanced production introduces risks of potential delays or non-compliance, which could impact production and revenue.
Market Penetration Risks for ASCENIV: While ASCENIV is early in its penetration curve, its growth depends on sustained prescriber adoption, payer access, and market confidence in supply continuity. Any disruptions in these areas could hinder its growth trajectory.
Leadership Transition Risks: The retirement of the CFO and the transition to a new CFO could pose risks related to continuity in financial strategy and execution during the transition period.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
ASCENIV Utilization and Market Penetration: ASCENIV is expected to sustain utilization growth throughout 2026 and beyond, driven by broad payer access, increasing prescriber adoption, and confidence in long-term supply continuity. The product is still early in its penetration curve within its total addressable market.
Working Capital and Cash Conversion: Accounts receivable and days sales outstanding are expected to improve over the course of 2026, trending toward or improving beyond industry benchmarks. Improved working capital efficiency and cash conversion are anticipated as demand builds and distribution agreements ramp up.
Revenue and Financial Projections for 2026-2029: For 2026, total revenue is expected to exceed $635 million, adjusted net income to exceed $255 million, and adjusted EBITDA to exceed $360 million. For 2027, total revenue is expected to exceed $775 million, adjusted net income to exceed $315 million, and adjusted EBITDA to exceed $455 million. For 2029, total revenue is expected to exceed $1.1 billion, and adjusted EBITDA to exceed $700 million.
Yield-Enhanced Production: 2026 will be the first full year of yield-enhanced production, supporting meaningful gross margin growth and increasing earnings power.
Plasma Collection Network and Supply Visibility: The strategic repositioning of the plasma collection network is expected to enhance capital efficiency and secure diversified long-term supply visibility through the late 2030s. This includes accretive cost savings beginning in 2026.
Pipeline Asset SG-001: A pre-IND package for SG-001 is anticipated to be submitted in 2026, potentially enabling progression into a cost-efficient registrational trial. SG-001 is viewed as a potential $300 million to $500 million peak annual revenue opportunity.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the updated expectation for ASCENIV's role in the product mix and revenue guidance?
A:ASCENIV showed a 51% year-over-year growth, contributing $363 million. The company expects a 70-30 split between ASCENIV and BIVIGAM by 2025, with ASCENIV's share continuing to grow. Gross margins were 63.8% in Q4 and 57.2% for the full year, expected to improve further. BIVIGAM is forecasted to remain flat or decline through 2026.
Q:What is the update on third-party supply contracts for RSV plasma?
A:Third-party supply agreements are performing well, with plasma collection increasing monthly. A new contract was signed with the acquirer of three divested plasma centers, adding about 30 centers with plans to expand to 50. Currently, high-titer plasma is being collected from over 280 centers. Less than 10% of donors meet the required antibody profile, but collection efforts are normalized and exceeding expectations.
Q:What is the offensive strategy for ASCENIV in terms of new centers and prescriber base expansion?
A:The company actively calls on about 300 immunologists, with most having prescribed ASCENIV. They aim to expand to new institutions and prescribers while deepening usage in existing ones. A new distribution agreement with McKesson is expected to open access to more institutions. Revenue guidance for 2025 is $510 million, growing to $635 million in 2026, driven by ASCENIV utilization.
Q:When will McKesson show up in receivables, and what is the normalized level?
A:McKesson is expected to appear in receivables in the first half of the year, with significant materialization in the latter half. Inventory and accounts receivable are expected to normalize by mid-to-late year. ASCENIV's higher cost per infusion and robust growth have increased working capital requirements for distributors and end-users.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the exact number of new centers or prescribers expected to be added in 2026, as well as the precise timeline for normalization of inventory and accounts receivable. Additionally, while they mentioned substantial progress with McKesson, they did not provide clear metrics or timelines for its impact on revenue.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ACAAI Conference
ADMA Chief
ADMA center
ADMA profitability
ASCENIV market
ASCENIV penetration
ASCENIV utilization
CEO Director
CFO
Co Founder
Founder President
Kohler
President CEO
capital efficiency
cash conversion
cash generation
change
continuity
contribution ADMA
differentiation
discipline
distribution
durability
dynamic
income result
network capital
plasma center
plasma collection
power
profile
record
supply agreement
supply visibility
term supply
track
transformation
transition
ADMA Transcript
ADMA Biologics, Inc. (ADMA) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call summary indicates strong financial performance with a 20% YoY revenue increase and improved gross margin. Despite a net loss, the reduction from the previous year shows progress. Positive cash flow and increased operating expenses suggest strategic investments. However, risks such as regulatory and supply chain challenges were noted, but no major negative sentiment was evident in the Q&A section. Given the company's market cap and the financial improvements, a positive stock price movement of 2% to 8% is likely over the next two weeks.
ADMA Biologics, Inc. (ADMA) Q4 2025 Earnings Call Transcript
Positive2-25
The earnings call summary reveals strong financial performance with record high revenue and margins, optimistic guidance, and effective strategies for ASCENIV's growth. The Q&A section indicates positive analyst sentiment and successful third-party supply contracts. Despite some risks and uncertainties, the company's robust financial health, strategic partnerships, and growth prospects outweigh potential negatives, suggesting a positive stock price movement.
ADMA Biologics, Inc. (ADMA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
ADMA Biologics, Inc. (ADMA) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call summary presents strong financial metrics, including a 10% QoQ revenue increase and significant gross margin expansion. The Q&A reveals optimism about ASCENIV's market potential and raised 2026 guidance, despite some management ambiguity. No negative trends were identified. Given the market cap, a positive stock price movement (2% to 8%) is anticipated due to strong financial performance, optimistic guidance, and strategic growth initiatives.
ADMA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
